MWMichael A. Wortley

Michael A. Wortley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael A. Wortley has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Eric Dubuis

    Respiratory Pharmacology, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom

    7 shared publications
  • Maria G. Belvisi

    Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    7 shared publications
  • Sara Jane Bonvini

    Respiratory Pharmacology, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK

    6 shared publications
  • Mark A. Birrell

    Respiratory Pharmacology, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, UK

    5 shared publications
  • John J. Adcock

    Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    4 shared publications
  • Sarah A. Maher

    Respiratory Pharmacology Group, Division of Airway Disease, National Heart and Lung Institute, Imperial College London, United Kingdom

    4 shared publications

Latest Publications

  • Surfactant found in cleaning products, 4-tert-octylphenol, causes airway sensory nerves firing and airway smooth muscle contraction

    by Billy Peter Baxter, Sara J. Bonvini, Michael A. Wortley, Eric D. Dubuis, John J. Adcock, Fisnik Shala, James Bolaji, Mark A. Birrell, Teresa D. Tetley, Maria G. Belvisi

    Research suggests that cleaning product exposure has adverse effects on respiratory health (Svanes, Ø. et al. AJRCCM 2018;197:1157-1163). This could be attributed to the activation of airway sensory nerves, which cause reflex coughing, and bronchospasm with associated shortness of breath. We hypothesised that alkylphenols, which are commonly used as non-ionic surfactants in cleaning products (Suen, J.L. et al. KJMS 2012;28:43-48), may induce adverse respiratory effects following exposure. The prevalent alkylphenol, 4-tert-octylphenol (4-t-OP), was investigated in vitro using vagus nerve and airway smooth muscle tissue from guinea pigs and in vivo using electrophysiology recordings of single afferent nerve fibres. 4-t-OP caused depolarisation of vagus nerves in vitro and single nerve firing in vivo, suggesting it can activate airway sensory nerves. 4-t-OP also increased tracheal pressure in vivo and airway smooth muscle contraction in vitro, indicating it can induce bronchospasm. We then pharmacologically investigated ion channels known to play a role in airway reflexes and determined that antagonists for TRPM3 (isosakuranetin, 5µM) and TRPV4 (GSK2193874, 10µM) inhibited 4-t-OP (10µM)-induced nerve depolarisation by 56% and 44% respectively. The same antagonists inhibited 4-t-OP-induced smooth muscle contraction by 39% and 30%. This suggests that 4-t-OP acts via two distinct pathways involving TRPM3 and TRPV4. Our data shows that 4-t-OP interacts with airway sensory nerves and airway smooth muscle via activation of TRPM3 and TRPV4, suggesting a novel mechanism by which alkylphenols may contribute to respiratory symptoms following cleaning product exposure.

  • Modelling IPF-associated chronic cough: role for oxidative stress?

    by Jonathan Miles, James W Pinkerton, Sara J Bonvini, Eric Dubuis, Michael A Wortley, Silvia Pontis, Marcello Trevisani, Gino Villetti, Riccardo Patacchini, Philip L Molyneaux, et al.

    Introduction: Chronic cough is a key symptom that plagues the lives of IPF patients, indeed, it is often the reason the disease is initially diagnosed. The aim of this project was to develop a pre-clinical model of IPF-associated cough and compare the mediator profiles with clinical samples, to aid in the search for effective treatments. Methods: Male guinea pigs (around 325g) were intratracheally dosed with vehicle (saline) or bleomycin (6 USP/kg) and coughs were quantified through manual observation of in-cage video footage, by watching 4.5 hours a day, for 3 weeks. Lung tissue, bronchoalveolar lavage fluid (BALF) and blood was harvested from a parallel group of animals. These were used to assess the extent of fibrosis and measure mediator production (e.g. a marker of oxidative stress: 8-isoprostane). Human BALF was obtained from IPF patients and healthy controls. Results: Spontaneous coughing was recorded in guinea pigs given bleomycin, which was associated with an increase in lung fibrosis and BALF 8-isoprostane (a marker of oxidative stress). We noted similar increases in BALF 8-isoprostane levels in the clinical samples. Conclusions: We have developed a preclinical model to aid in the search for a treatment for IPF-associated coughing. Furthermore, initial data suggests that an increase in oxidative burden (a known trigger of coughing) could be an attractive target.

  • XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 Antagonist, Does Not Reduce Cough in Patients with Refractory Cough

    by Maria G. Belvisi, Mark A. Birrell, Michael A. Wortley, Sarah A. Maher, Imran Satia, Huda Badri, Kimberley Holt, Patrick Round, Lorcan McGarvey, John Ford, et al.

    Rationale: Heightened cough responses to inhaled capsaicin, a transient receptor potential vanilloid 1 (TRPV1) agonist, are characteristic of patients with chronic cough. However, previously, a TRPV1 antagonist (SB-705498) failed to improve spontaneous cough frequency in these patients, despite small reductions in capsaicin-evoked cough. Objectives: XEN-D0501 (a potent TRPV1 antagonist) was compared with SB-705498 in preclinical studies to establish whether an improved efficacy profile would support a further clinical trial of XEN-D0501 in refractory chronic cough. Methods: XEN-D0501 and SB-705498 were profiled against capsaicin in a sensory nerve activation assay and in vivo potency established against capsaicin-induced cough in the guinea pig. Twenty patients with refractory chronic cough participated in a double-blind, randomized, placebo-controlled crossover study evaluating the effect of 14 days of XEN-D0501 (oral, 4 mg twice daily) versus placebo on awake cough frequency (primary outcome), capsaicin-evoked cough, and patient-reported outcomes. Measurements and Main Results: XEN-D0501 was more efficacious and 1,000-fold more potent than SB-705498 at inhibiting capsaicin-induced depolarization of guinea pig and human isolated vagus nerve. In vivo XEN-D0501 completely inhibited capsaicin-induced cough, whereas 100 times more SB-705498 was required to achieve the same effect. In patients, XEN-D0501 substantially reduced maximal cough responses to capsaicin (mean change from baseline, XEN-D0501, −19.3 ± 16.4) coughs; placebo, −1.8 ± 5.8 coughs; P < 0.0001), but not spontaneous awake cough frequency (mean change from baseline, XEN-D0501, 6.7 ± 16.9 coughs/h; placebo, 0.4 ± 13.7 coughs/h; P = 0.41). Conclusions: XEN-D0501 demonstrated superior efficacy and potency in preclinical and clinical capsaicin challenge studies; despite this improved pharmacodynamic profile, spontaneous cough frequency did not improve, ruling out TRPV1 as an effective therapeutic target for refractory cough. Clinical trial registered with www.clinicaltrialsregister.eu (2014-000306-36).


  • The role of adenylyl cyclase isoform 6 in β‐adrenoceptor signalling in murine airways

    by Mark A Birrell, Sara J Bonvini, Michael A Wortley, James Buckley, Liang Yew‐Booth, Sarah A Maher, Nicole Dale, Eric D Dubuis, Maria G Belvisi

    Background and Purpose: Adenylyl cyclase (AC) is a key signalling enzyme for many GPCRs and catalyses the conversion of ATP to cAMP which, in turn, is a crucial determinant of many biological responses. β‐Adrenoceptor agonists are prescribed as bronchodilators for asthma and chronic obstructive pulmonary disease, and it is commonly assumed that they elicit their actions via AC‐dependent production of cAMP. However, empirical evidence in support of this is lacking and the exact mechanism by which these drugs acts remains elusive. This is partly due to the existence of at least 10 different isoforms of AC and the absence of any truly selective pharmacological inhibitors. Here, we have used genetically modified mice and model systems to establish the role of AC isoforms in the airway responses to β‐adrenoceptor agonists.Experimental Approach: Receptors mediating responses to β‐adrenoceptor agonists in airway smooth muscle (ASM) and sensory nerve were identified in isolated tissue systems. Expression of mRNA for the AC isoforms in ASM and neurones was determined by qPCR. Functional responses were assessed in AC isoform KO mice and wild‐type controls.Key Results: Airway and vagal tissue expressed mRNA for various isoforms of AC. AC6 was the most prominent isoform. Responses to β‐adrenoceptor agonists in tissues from AC6 KO mice were virtually abolished.Conclusions and Implications: AC6 played a critical role in relaxation of ASM to β1‐adrenoceptor agonists and in modulation of sensory nerves by β1‐3‐adrenoceptor agonists. These results further unravel the signalling pathway of this extensively prescribed class of medicine.


  • Prostaglandin D2and the role of the DP1, DP2and TP receptors in the control of airway reflex events

    by Sarah A. Maher, Mark A. Birrell, John J. Adcock, Michael A. Wortley, Eric D. Dubuis, Sara J. Bonvini, Megan S. Grace, Maria G. Belvisi

    Prostaglandin D2(PGD2) causes cough and levels are increased in asthma suggesting that it may contribute to symptoms. Although the prostaglandin D2receptor 2 (DP2) is a target for numerous drug discovery programmes little is known about the actions of PGD2on sensory nerves and cough.We used human and guinea pig bioassays,in vivoelectrophysiology and a guinea pig conscious cough model to assess the effect of prostaglandin D2receptor (DP1), DP2and thromboxane receptor antagonism on PGD2responses.PGD2caused cough in a conscious guinea pig model and an increase in calcium in airway jugular ganglia. Using pharmacology and receptor-deficient mice we showed that the DP1receptor mediates sensory nerve activation in mouse, guinea pig and human vagal afferents.In vivo, PGD2and a DP1receptor agonist, but not a DP2receptor agonist, activated single airway C-fibres. Interestingly, activation of DP2inhibited sensory nerve firing to capsaicinin vitroandin vivo.The DP1receptor could be a therapeutic target for symptoms associated with asthma. Where endogenous PGD2levels are elevated, loss of DP2receptor-mediated inhibition of sensory nerves may lead to an increase in vagally associated symptoms and the potential for such adverse effects should be investigated in clinical studies with DP2antagonists.


  • Open Access

    Theophylline inhibits the cough reflex through a novel mechanism of action

    by Eric Dubuis, Michael A. Wortley, Megan S. Grace, Sarah A. Maher, John J. Adcock, Mark A. Birrell, Maria G. Belvisi


  • Open Access

    Tiotropium modulates transient receptor potential V1 (TRPV1) in airway sensory nerves: A beneficial off-target effect?⋆

    by Mark A. Birrell, Sara J. Bonvini, Eric Dubuis, Sarah A. Maher, Michael A. Wortley, Megan S. Grace, Kristof Raemdonck, John J. Adcock, Maria G. Belvisi


  • Open Access

    Harvesting, Isolation, and Functional Assessment of Primary Vagal Ganglia Cells

    by Eric Dubuis, Megan Grace, Michael A. Wortley, Mark A. Birrell, Maria G. Belvisi

    Airway sensory nerves play an important defensive role in the lungs, being central in mediating protective responses like cough and bronchoconstriction. In some cases, these responses become excessive, hypersensitive, and deleterious. Understanding the normal function of airway nerves and phenotype changes associated with disease will help in developing new therapeutics for treating chronic obstructive pulmonary disease and chronic cough. Guinea pigs, and to a lesser extent ferrets, are commonly employed for studying the cough reflex because they have a cough response similar to humans. While rats and mice do not exhibit a cough response, they do possess sensory nerves that respond to the same range of tussive stimuli as guinea pigs and humans. Described in this unit are protocols for harvesting guinea pig, mouse, and rat sensory nerve cell bodies to assess molecular and functional changes associated with pulmonary disease, and to identify new targets for therapeutic intervention. Curr. Protoc. Pharmacol. 62:12.15.1‐12.15.27. © 2013 by John Wiley & Sons, Inc.


  • Pharmacology of Cough

    by Maria G. Belvisi, Megan Grace, Sarah Maher, Michael Wortley, Eric Dubuis, John Adcock, Sara Bonvini, Mark A. Birrell